This can help individuals feel fuller for longer and can promote weight loss. When measured by traditional weight loss ...

Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.

Today, the American Diabetes Association® (ADA) announced the awardees of the 2025 Pathway to Stop Diabetes® (Pathway) grants.  This year's grants dedicate more than $6.1 million to support ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

In the Indian stock market, FIIs are booking profits, domestic investors are treading carefully, and valuations are stretched ...

Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted U.S. patent US 12,186,299 dated Jan. 7, 2025, Compositions And Methods For Treating ...

Aptar has a narrow economic moat, with durable switching costs in the Pharma business supported by intangible assets throughout the product portfolio from expertise in product regulation, design, and ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The Trump administration’s cuts to university research grants will make America sicker and poorer in the long run.

Vermont businesses are weighing in about prospective tariffs. President Donald Trump threatened to place a 25 percent tariff ...

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group with a market capitalization of $15.11 million, is ...